An EU deal on medicines is vital for patients

RPS President Sandra Gidley comments on the latest news on Brexit negotiations:

“The last few days have seen little visible progress on how the UK and EU will cooperate on medicines and health at the end of the transition period.

“Organisations across health and care will be looking to all parties to redouble their efforts on key issues such as access to medicines, the Falsified Medicines Directive, research funding, clinical trials, workforce and supporting our world-leading pharmaceutical industry.

“Amid the global pandemic of COVID-19, it’s vital the UK and EU to continue to work together to secure an agreement in the interests of patient care across Europe.”